FDA clears Precision BioSciences’ IND for PBGENE-HBV to treat HBV
Precision BioSciences (DTIL) announced that the U.S. Food and Drug Administration or FDA has cleared the Investigational New Drug application ...
Precision Medicine Online23h
Precision BioSciences Nets FDA Clearance to Start Hepatitis B Gene-Editing Drug Trial
The US joins Moldova, Hong Kong, and New Zealand as countries to greenlight the company's Phase I trial of PBGENE-HBV.
Hosted on MSN1mon
SCG’s HBV T-cell therapy shows promise in Phase I trial
The therapy, which targets hepatitis B surface antigen (HBsAg), showed substantial ... Medical Products Administration (NMPA), the US Food and Drug Administration (FDA), the Hong Kong Department ...